Welcome to our dedicated page for HLUYY news (Ticker: HLUYY), a resource for investors and traders seeking the latest updates and insights on HLUYY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HLUYY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HLUYY's position in the market.
Otsuka Pharmaceutical and Lundbeck have announced positive Phase 3 clinical trial results for brexpiprazole, aimed at treating agitation in Alzheimer’s dementia. In a double-blind study with 345 participants, treatment with brexpiprazole showed a statistically significant reduction in agitation compared to placebo. Agitation is a common symptom affecting 45% of Alzheimer’s patients, leading to increased caregiver burden and health risks. The data will support a Supplemental New Drug Application to the FDA, which previously granted brexpiprazole fast track designation for this indication.
Otsuka Pharmaceutical and H. Lundbeck A/S announced positive findings from a Phase 3 study of brexpiprazole targeting agitation in Alzheimer's dementia. The results, to be presented at the 2022 Alzheimer’s Association International Conference on August 4, highlight a potential treatment option for a significant unmet medical need, as no FDA-approved drugs currently exist for this condition. The study aims to improve the quality of life for patients and caregivers facing this prevalent issue.
Otsuka Pharmaceutical and Lundbeck have announced positive Phase 3 clinical trial results for brexpiprazole in treating agitation in patients with Alzheimer’s dementia. The study showed a statistically significant reduction in agitation compared to placebo (p=0.0026). Agitation affects approximately 45% of Alzheimer’s patients, leading to increased caregiver burden. Despite no FDA-approved treatments currently available, the results pave the way for a Supplemental New Drug Application (sNDA) to the FDA by late 2022, based on this and two previous trials.
FAQ
What is the market cap of HLUYY (HLUYY)?
